Elicio Therapeutics, Inc.

General Information

(Note: Elicio Therapeutics, Inc. withdrew its IPO plans in an SEC filing dated Sept. 13, 2022. The IPO was postponed in late July 2021. Elicio Therapeutics filed its S-1 in June 2021.) 

We are a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation at the unique location where adaptive immune responses are generated. Our proprietary Amphiphile, or AMP, platform delivers immunotherapeutics directly to the “brain center” of the immune system – the lymph nodes. We believe this site-specific delivery of disease-specific antigens, adjuvants and other immunomodulators will more efficiently educate, activate, and amplify critical immune cells, resulting in induction and persistence of potent adaptive immunity required to treat many diseases. In preclinical models, we have observed lymph-node specific engagement driving therapeutic immune responses of increased magnitude, function and durability. We believe our AMP lymph node targeted approach will produce superior clinical benefits compared to immunotherapies that do not engage the lymph nodes.

Our lead product candidate, ELI-002, is being developed to treat cancers driven by KRAS, a mutation found in approximately 25% of tumors. We are conducting a Phase 1/2 clinical trial of ELI-002 (AMPLIFY-201) and anticipate initial safety, dose escalation, and correlative biomarker data in the first half of 2022.

We are also evaluating the potential use of ELI-004, our universal AMP-modified CpG adjuvant, and a component of ELI-002, in conjunction with other disease-specific antigens, to treat or prevent additional diseases.

(Note: Elicio Therapeutics postponed its IPO on July 28, 2021.)


Employees: 22
Founded: 2011
Contact Information
Address One Kendall Square, Suite 14303, Cambridge, MA 02139
Phone Number (857) 209-0050.
Web Address http://www.elicio.com/
View Prospectus: Elicio Therapeutics, Inc.
Financial Information
Market Cap $180.44mil
Revenues $0 mil (last 12 months)
Net Income $-18.9 mil (last 12 months)
IPO Profile
Symbol ELTX
Exchange NASDAQ
Shares (millions): 3.1
Price range $12.00 - $14.00
Est. $ Volume $40.0 mil
Manager / Joint Managers BTIG/ Oppenheimer & Co.
CO-Managers National Securities
Expected To Trade: 7/26/2021
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change